Efficacy Assessment Criteria Based on Risk and Cost

Roberts EB , Levy RI , Frankelstein SN , Moskowitz J , Sonolik EJ . Biomedical Innovation. Cambridge: MIT Press, 1981.

Health Care Technology Institute. The dialogue of device innova- tion: an overview of the medical technology innovation process. Gei- gle & Associates. November 1993.

Terrin ML . Efficient use of endpoints in clinical trials: a clinical per- spective. Stat Med 1990;9(1-2):155–160.

Boisel JP , Collet JP , Moleur P , Haugh M. Surrogate endpoints: a basis for a rational approach. Eur J Clin Pharmacol 1992;43:235–244.

Dellinger RP . Clinical trials in ARDS. New Horizons 1993;1:584–592.

Benson JS . A look at the progress of the Food and Drug Adminis- tration's medical device program. Food Drug Cosmet Law J 1985;40:95–102.

FDA. Potential harm is key to significant risk decisions. Devices Diagn Lett 1986;13:1–2.

Kessler DA , Pape SM , Sundwall DN . The federal regulation of med- ical devices. N Engl J Med 1987;317(6):357–366.

Sherertz RJ , Steed SA . Medical devices: significant risk vs non- significant risk. JAMA 1994;272(12):955–956.

Technology assessment task force of the Society of Critical Care Medicine. A model for technology assessment applied to pulse oxime- try. Crit Care Med 1993;21(4):615–624.

Bucci VA , Reiss JB . Technology assessment of medical devices under Medicare: who should examine "safety and effectiveness?" Food Drug Cosmet Law J 1985;40:445–455.

Anderson G , Steinberg E. To buy or not to buy: technology acquisition under prospective payment. N Engl J Med 1984;311(3):182–185.

Kane NM , Manoukian PD . The effect of the Medicare prospective payment system on the adoption of new technology: the case of coch- lear implants. N Engl J Med 1989;321(20):1378–1383.

Trajtenberg M. Economic analysis of product innovation: the case of CT scanners. Cambridge: Harvard Univ Press, 1990.